Sugi Predict

Sugi Predict / Compounds / SCHEMBL19627636

SCHEMBL19627636

SCHEMBL19627636

C[C@@H]1CC(O)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.50
▸ CHRM1 P11229 1/20 0.50
▸ CHRM3 P20309 1/20 0.50
▸ GPR119 Q8TDV5 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.40
▸ PREP P48147 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ USP2 O75604 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ RECQL P46063 1/20 0.37
▸ EPHX1 P07099 1/20 0.37
▸ NR1H2 P55055 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19627634 1.00 CHRM2 (0.50) CHRM2CHRM1CHRM3GPR119HSD17B10
SCHEMBL19634252 1.00 CHRM2 (0.50) CHRM2CHRM1CHRM3GPR119HSD17B10
SCHEMBL14959447 1.00 CHRM2 (0.50) CHRM2CHRM1CHRM3GPR119HSD17B10
SCHEMBL2505132 1.00 CHRM2 (0.50) CHRM2CHRM1CHRM3GPR119HSD17B10
SCHEMBL9311281 1.00 CHRM2 (0.50) CHRM2CHRM1CHRM3GPR119HSD17B10
SCHEMBL8934285 1.00 CHRM2 (0.50) CHRM2CHRM1CHRM3GPR119HSD17B10
SCHEMBL9312524 1.00 CHRM2 (0.50) CHRM2CHRM1CHRM3GPR119HSD17B10
SCHEMBL8934384 1.00 CHRM2 (0.50) CHRM2CHRM1CHRM3GPR119HSD17B10
SCHEMBL30045327 0.91 CHRM2 (0.43) CHRM2CHRM1CHRM3GPR119HSD17B10
SCHEMBL21257391 0.90 CHRM2 (0.47) CHRM2CHRM1CHRM3HSD17B10PREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540131-B2 N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof MERCK SHARP & DOHME LLC (US) 2026-02-03 — — US disclosed
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-09-04 — — US disclosed
EP-4536650-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
CN-119317623-A Tricyclic quinolone BCL6 bifunctional degradation agents 树线生物科学公司 2025-01-14 — — CN disclosed
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2024-08-29 — — US disclosed
CN-117510465-A 5, 6-diphenyl pyrazine-2-piperidine compound and preparation method and application thereof 四川轻化工大学 2024-02-06 — — CN disclosed
WO-2023240038-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-14 — — WO disclosed
US-20230023066-A1 N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2023-01-26 — — US disclosed
CN-115243687-A N- (heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions and uses thereof 默沙东有限责任公司 2022-10-25 — — CN disclosed
EP-4048261-A1 N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Merck Sharp & Dohme LLC (US) 2022-08-31 — — EP disclosed
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 — — US disclosed
WO-2021080929-A1 N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2021-04-29 — — WO disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 — — US disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 — — WO disclosed
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540131-B2 N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof LRRK2, PARK7, SNCA CHRM2 1460/4885CHRM1 1556/4885CHRM3 1732/4885
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR CHRM2 4791/4885CHRM1 4784/4885CHRM3 4868/4885
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C CHRM2 325/4885CHRM1 462/4885CHRM3 575/4885
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR CHRM2 4791/4885CHRM1 4784/4885CHRM3 4868/4885
US-20230023066-A1 N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF LRRK2, CLK2, PARK7 CHRM2 1670/4885CHRM1 2661/4885CHRM3 2217/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C CHRM2 325/4885CHRM1 462/4885CHRM3 575/4885
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B CHRM2 1497/4885CHRM1 2022/4885CHRM3 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.